In order to improve the selectivity of pathological EGFR and wild-type EGFR, scientists have developed the third-generation inhibitors, such as the CO-1686 (rociletinib) and AZD9291 (osimertinib), which were approved for the treatment of locally advanced or metastatic EGFRT790M mutation-positive NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.